|
"... Alternative Sources of Cells Our transplantation technologies may incorporate autologous cells, donor cells or other sources of cells including insulin responsive cells derived from human-stem cells or islet derived from xenogeneic sources, depending on the clinical indication under evaluation and the need for expanded numbers of cells for treatment of larger populations. As such, we will continue to work with academic collaborators and industry partners to identify and secure the required cells for our therapeutic indications. In this regard, Sernova has agreed on key terms with the University Health Network of Toronto (UHN) to gain access to worldwide, exclusive rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller, for the advancement of glucose-responsive insulin-producing stem cells for the treatment of patients with insulin-dependent diabetes. Sernova and UHN have entered into a non-binding Term Sheet with an exclusive negotiation period which outlines the terms of the definitive license agreement for the granting of an exclusive license to Sernova covering all patent rights relating to the UHN stem cell technologies including for the treatment of diabetes. A manufacture and product development program is also being developed. Sernova’s rights to the UHN stem cell technologies are subject to negotiation and execution of a definitive license agreement with UHN. ..." Quelle: MD&A vom 29.6.2015 |
|
| aus der Diskussion: | Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! |
| Autor (Datum des Eintrages): | techinvestor69 (29.06.15 20:13:31) |
| Beitrag: | 34 von 8,568 (ID:50076231) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |